Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8789986 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
The results of this study indicate that in patients with a BCG-relapsing tumor after the initial BCG therapy, the same BCG strain as that administered at the initial BCG therapy could be utilized effectively for the second BCG therapy. Patients treated with BCG Tokyo-172 for an initial tumor had a higher incidence of side effects during the second BCG therapy using the same strain.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Naoya M.D., Eiji M.D., Ph.D., Kazuhiro M.D., Takeo M.D., Ph.D., Ryuichi M.D., Ph.D., Mototsugu M.D., Ph.D.,